Quality of life in patients receiving medicines for prostate cancer: What do clinicians think is important?

Emma Dunlop, Steven Karlsson-Brown, Jennifer Laskey, Marion Bennie, Kelly Baillie, Julie Clarke

Research output: Contribution to journalMeeting abstract

34 Downloads (Pure)

Abstract

Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.
Original languageEnglish
Pages (from-to)54-55
Number of pages2
JournalJournal of Oncology Pharmacy Practice
Volume24
Issue number8
Publication statusPublished - 1 Dec 2018
Event21st Annual BOPA Symposium - Birmingham, United Kingdom
Duration: 12 Oct 201814 Oct 2018

Keywords

  • PROMs
  • cancer medicines
  • pharmacy
  • quality of life

Cite this